Genzyme and Arecor will work together on developing advanced formulations for protein therapeutics.

Both companies say they want to develop stable, high-strength formulations of labile biomolecules as part of a two-year working relationship where Arecor’s technologies will be used to improve on conventional approaches in protein formulation.

Genzyme vice president of therapeutic protein R&D Robert Mattaliano said the Arecor technology has demonstrated the potential to significantly improve the stability of complex biologicals by using novel formulation design principles.

“Genzyme is pleased to establish this strategic partnership in support of our goal to provide stable and convenient dosage forms to patients and their caregivers,” Mattaliano said.

Arecor CEO Tom Saylor said the formulation of next generation biologics represents unique challenges to developers.

“Arecor has developed a strong partnership with Genzyme and is privileged to work closely with one of the world leaders in biotechnology to help enable new protein-based therapeutics,” Saylor said.